Preclinical studies have demonstrated that silencing of MALAT1, HOTAIR, or SAMMSON using antisense oligonucleotides (ASOs) or gapmeRs dramatically reduces intratumoral vessel density and tumour growth and shows synergistic effects with BRAF/MEK inhibitors and bevacizumab. This evidence concerns the gene BRAF and neoplasm.